Login to Your Account

Fibrocell’s Laviv: The Other Autologous Cell Therapy Story

By Jennifer Boggs
Managing Editor

Thursday, October 3, 2013
Mention autologous cell therapy and Dendreon Corp.’s commercially challenged prostate cancer vaccine Provenge (sipuleucel-T) usually comes first to mind. Despite an innovative scientific approach – using a patient’s own cells in a personalized treatment – the product’s sales have been hampered by manufacturing complexity, reimbursement issues and increasing competition in the prostate cancer space, so much so that even the much-awaited European approval provoked little excitement. (See BioWorld Today, Sept. 18, 2013.)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription